On Invalid Date, Inmed Pharmaceuticals (NASDAQ: INM) reported Q1 2024 earnings per share (EPS) of -$0.18, up 70% year over year. Total Inmed Pharmaceuticals earnings for the quarter were -$1.72 million. In the same quarter last year, Inmed Pharmaceuticals's earnings per share (EPS) was -$0.60.
As of Q2 2024, Inmed Pharmaceuticals's earnings has grown year over year. Inmed Pharmaceuticals's earnings in the past year totalled -$6.08 million.
What was INM's revenue last quarter?
On Invalid Date, Inmed Pharmaceuticals (NASDAQ: INM) reported Q1 2024 revenue of $1.17 million up 13.41% year over year. In the same quarter last year, Inmed Pharmaceuticals's revenue was $1.03 million.
What was INM's revenue growth in the past year?
As of Q2 2024, Inmed Pharmaceuticals's revenue has grown 140.49% year over year. This is 56.81 percentage points higher than the US Biotechnology industry revenue growth rate of 83.69%. Inmed Pharmaceuticals's revenue in the past year totalled $5.63 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.